Drug intelligence / Profile preview

mosunetuzumab + lenalidomide

Development stage: Unknown
Lead developer: Genentech
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Small Molecules
Administration: Intravenous, Oral

Overview

Mosunetuzumab + lenalidomide is an investigational combination therapy being evaluated for the treatment of follicular lymphoma. Mosunetuzumab is a CD20xCD3 bispecific antibody that redirects T cells to engage and eliminate malignant B cells, while lenalidomide is a potent immunomodulatory agent that can stop cancer cells from developing and help the immune system attack cancer cells. The combination is designed to provide synergistic effects in treating lymphoma, particularly in relapsed/refractory settings.

Other names: M+LenMosun+LenM-Len

Targets

CRBN (Cereblon)CD20 (B-lymphocyte antigen CD20)CD3 (T-cell surface glycoprotein CD3)

Beyond the preview

Go deeper on mosunetuzumab + lenalidomide.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on mosunetuzumab + lenalidomide.

Explore the full profile